



## MAYNE PHARMA ANNOUNCES PROPOSED ELECTION OF NON-EXECUTIVE DIRECTOR AND CHANGE OF AUDITOR

---

**27 October 2023, Adelaide, Australia:** Mayne Pharma Group Limited (ASX: MYX) has today released the notice of meeting for its Annual General Meeting (AGM) to be held at 10.00am (AEDT) on Thursday, 30 November 2023.

The Notice of Meeting includes resolutions related to the election of a new Non-Executive Director, and a change of external auditor.

### Proposed Appointment of new Non-Executive Director

Following the retirement of Dr Carolyn Myers from the Board in July 2023, the Board is recommending that shareholders elect Ms Anne Lockwood as a Non-Executive Director at the Company's AGM.

Ms Lockwood, an Australian resident, is the former CFO and Chief Commercial Officer of ASX-listed Integral Diagnostics (ASX: IDX) and current CFO of privately owned Planet Innovation. Prior to this, Ms Lockwood spent over 20 years in accounting roles including 18 years at EY.

Mayne Pharma's Chair Mr Frank Condella said, "The Board believes that Ms Lockwood's skills and experience as a finance executive will add value to the Board."

Ms Lockwood holds a Bachelor of Commerce with majors in Accounting and Law from Deakin University and is a chartered accountant and a fellow of the Institute of Chartered Accountants.

### Proposed Change of External Auditor

During 2023, the Company conducted a tender process in relation to its external audit arrangements. As a result of this tender process, and upon the recommendation of Management and the Audit and Risk Committee, the Board recommends that, subject to ASIC consenting to the resignation of EY, the Company appoint BDO Audit Pty Ltd as the Company's external auditor. The Board believes that the appointment of BDO Audit Pty Ltd is in the best interests of the Company and its shareholders.

EY has advised the Company that it has applied to ASIC for consent to resign as the Company's auditor with effect from the close of the AGM. ASIC's consent to EY's resignation is required under section 329 of the *Corporations Act 2001* (Cth). At the date of this announcement, ASIC's consent is yet to be received. An update on whether ASIC has provided its consent will be provided prior to the AGM.



## ASX Announcement

For further information contact:

Australia:

Craig Haskins

+61 421 029 843

[ir@maynepharma.com](mailto:ir@maynepharma.com)

USA:

Lisa M. Wilson

+1 917-543-9932

[ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Chair

### About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com).